Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

120P - The predictive value of LATS1 mutation for immune checkpoint inhibitors therapy in bladder cancer

Date

10 Sep 2022

Session

Poster session 01

Topics

Tumour Immunology

Tumour Site

Genitourinary Cancers

Presenters

junjun Li

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

J. Li1, Q. Zhang2, Y. Tan2, Q. Duan2, T. Sun2, C. Qi2

Author affiliations

  • 1 Pathological Diagnostic Centre, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013 - Changsha/CN
  • 2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 210042 - Nanjing/CN
More

Abstract 120P

Background

As a key regulator of hippo signaling pathway, LATS1 (large tumor suppressor 1) gene encodes a Ser/Thr protein kinase which plays a crucial role in cellular transformation and tumorigenesis. But it remains to be determined if LATS1 mutation may have true biologic relevance and can independently predict responses to immune checkpoint inhibitors (ICIs). Our research aims to elucidate its mutation association with ICI efficacy.

Methods

In order to investigate the correlation between LATS1 mutation and ICI efficacy in the bladder cancer, we used cBioportal to collect clinical and mutation data of 215 ICI-treated bladder cancers from MSKCC cohort. Gene expression and WES data of 413 samples were obtained from the TCGA database for further analysis of the differences of potential biological mechanisms between LATS1-mutant and LATS1-wildtype tumors. Tumor mutation burden (TMB) was calculated as the total number of somatic non-synonymous mutations per megabase in both MSKCC and TCGA cohorts. CIBERSORT algorithm was applied to infer 22 human immune cell type proportions in TCGA advanced bladder cancers.

Results

In the MSKCC cohort, we observed 5.12% (11/215) patients harbored LATS1 mutation. As indicated by Kaplan-Meier analysis, the patients with LATS1 mutation had significantly better OS in the MSKCC cohort (P = 0.023, HR = 0.23, 95%CI: 0.06-0.93). This link was still existing when controlling for age, sex, stage, TMB and therapy type in the multivariate Cox regression analysis (P = 0.039, HR = 0.22, 95%CI = 0.05-0.93). As expected, the LATS1-mutant group had higher TMB than that of the LATS1-wildtype group in both the MSKCC cohort (median: 27.55 vs. 7.87, P <0.001) and TCGA cohort (median: 7.74 vs. 4.62, P = 0.042). Immune cell analysis showed that NK activated cells were abundant in the LATS1-mutant group (P = 0.05). This result indicated LATS1-mutant tumors had an activated antitumor immune microenvironment.

Conclusions

LATS1 mutations might be a potential biomarker to predict the efficacy of immunotherapy for bladder cancer. Considering the heterogeneity among the patients and other confounding factors, further prospective validation cohorts are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.